Answers are grounded in this paper and cite their sources.
Analytical and preclinical studies demonstrate a viable antimicrobial solution for MERS-CoV, suggesting effective emergency preparedness.
. To ensure stability and facilitate rapid deployment in outbreak scenarios, a lyophilized formulation of KNIH-88 was developed, maintaining structural integrity and biological activity under long-term storage. Collectively, these findings support KNIH-88 as a promising therapeutic antibody for MERS-CoV, combining potent antiviral efficacy, structural stability, and a formulation suitable for stockpiling and emergency use in endemic regions.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: